Sunny Pharmtech's generic product, Diazepam Injection (DZP-I), has received approval from the U.S. FDA and obtained an ANDA certification. The product is indicated for the treatment of anxiety. According to IQVIA database statistics, the total sales of this drug in the U.S. over the past year amounted to approximately USD 18.83 million. Sunny Pharmtech plans to market the product through its local partners in the United States.